Return to:
Cancer ArticlesOr:
Recent Cancer Articleshttp://www.cnbc.com/id/22776252/for/cnbcCNBC - SEATTLE (Thomson Financial) - Cell Therapeutics Inc said its cancer drug Zevalin was well tolerated and effective in a phase II clinical study which saw radioimmunotherapy (RIT) added to chemotherapy for previously untreated patients with non ...
Article Finder:
January 21, 2008 11:18:00 PM